Accuray Grants Equity Inducement Awards to New Executives
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: PRnewswire
- Executive Appointments and Incentives: Accuray has appointed Paul Miele as Chief Commercial Officer and David Shin as Chief Legal Officer, granting them 650,000 and 375,000 restricted stock units (RSUs) respectively, reflecting the company's commitment to investing in its executive team.
- Performance Incentive Structure: The performance-based restricted stock units (PSUs) awarded to Miele and Shin will vest based on performance targets set for the fiscal year ending in 2028, aiming to enhance executive motivation and align their interests with overall company performance.
- Equity Incentive Plan Details: Miele's RSUs will vest starting April 30, 2027, with one-fourth unlocking annually, while Shin's RSUs will begin vesting on January 29, 2027, ensuring both executives contribute value throughout their tenure.
- Company Strategic Direction: Accuray is dedicated to improving patient lives through innovative radiation therapy solutions, and these executive incentives not only enhance management stability but also reflect the company's strategic commitment to ongoing innovation and market expansion in the radiation therapy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARAY
Wall Street analysts forecast ARAY stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.378
Low
2.00
Averages
2.00
High
2.00
Current: 0.378
Low
2.00
Averages
2.00
High
2.00
About ARAY
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Accuray Grants Equity Inducement Awards to New Executives
- Executive Appointments and Incentives: Accuray has appointed Paul Miele as Chief Commercial Officer and David Shin as Chief Legal Officer, granting them 650,000 and 375,000 restricted stock units (RSUs) respectively, reflecting the company's commitment to investing in its executive team.
- Performance Incentive Structure: The performance-based restricted stock units (PSUs) awarded to Miele and Shin will vest based on performance targets set for the fiscal year ending in 2028, aiming to enhance executive motivation and align their interests with overall company performance.
- Equity Incentive Plan Details: Miele's RSUs will vest starting April 30, 2027, with one-fourth unlocking annually, while Shin's RSUs will begin vesting on January 29, 2027, ensuring both executives contribute value throughout their tenure.
- Company Strategic Direction: Accuray is dedicated to improving patient lives through innovative radiation therapy solutions, and these executive incentives not only enhance management stability but also reflect the company's strategic commitment to ongoing innovation and market expansion in the radiation therapy sector.
See More
Accuray Partners with University of Wisconsin for Cancer Treatment Innovation
- Strategic Collaboration: Accuray has signed a 10-year strategic collaboration agreement with the University of Wisconsin School of Medicine to leverage its Stellar™ adaptive radiation therapy platform for advancing personalized cancer treatments, marking a deepening of their long-standing partnership in precision radiation therapy technology development.
- Clinical Research Support: This collaboration will support clinical research, education, and the development of adaptive therapies, enabling medical teams to continually raise the standard of cancer care, thereby improving patient treatment outcomes and quality of life.
- Legacy and Innovation: Since the late 1980s, technology invented by the University of Wisconsin's professor team has been commercialized into Accuray's TomoTherapy® system, ushering in a new era in radiation medicine that enhances treatment precision and accuracy.
- Future Outlook: The partnership aims to accelerate the translation of research innovations into clinical practice, leveraging a robust academic-industry collaboration to advance personalized radiotherapy technologies that better serve patient needs.
See More
Accuray Shares Plunge 27% After Q3 Fiscal 2026 Earnings Miss Expectations
- Earnings Decline: Accuray reported total net revenue of $104.8 million for Q3, a 7% year-over-year decline that missed Wall Street expectations, resulting in a 27% drop in share price.
- Weak Product Sales: Product revenue fell 13% to $49.7 million, while service revenue slipped 1% to $55.1 million, indicating significant competitive pressures in the market.
- Rising Operating Costs: Operating expenses increased by 12% year-over-year to $34.4 million, which included $6.5 million in restructuring charges, exacerbating the company's financial strain.
- Withdrawal of Financial Guidance: Citing geopolitical uncertainties in key Middle Eastern markets, Accuray withdrew its financial outlook, with the CEO indicating a cautious approach to future performance assessments.
See More
Accuray Q3 Fiscal 2026 Earnings Call Insights
- Revenue Performance: Accuray reported total revenue of approximately $105 million for Q3, reflecting a 3% sequential increase but a 7% year-over-year decline, indicating market challenges amid geopolitical uncertainties.
- Product Shipment Delays: Shipments planned for customers in the Middle East, North Africa, and Pakistan have been indefinitely delayed due to geopolitical disruptions, which are expected to negatively impact service revenue and increase future performance uncertainty.
- Guidance Withdrawal: Management's decision to withdraw financial guidance reflects insufficient visibility on future revenue and adjusted EBITDA, with an expectation to realize at least $25 million in structural profitability improvements in fiscal 2027.
- Margin Pressure: The overall gross margin for the third quarter was 24.1%, down from 27.9% in the prior year, primarily due to increased parts consumption and tariff impacts, highlighting challenges in cost control.
See More
Accuray Inc. Withdraws FY2026 Financial Guidance Amid Geopolitical Uncertainty in the Middle East - SEC Filing
Financial Guidance Update: The financial guidance for FY 2026 has been withdrawn due to increasing geopolitical uncertainty in the Middle East.
Impact of Geopolitical Factors: The decision to withdraw guidance reflects concerns over the potential impact of regional instability on financial forecasts.
See More
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving market competitiveness.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in the medical technology sector, having previously served as Business Unit Leader at Johnson & Johnson MedTech, where he successfully reversed a revenue decline trend and achieved double-digit annual sales growth.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to enhance the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to further drive growth in systems and services sales, particularly in providing value-added solutions to customers.
See More
Accuray Grants Equity Inducement Awards to New Executives
- Executive Appointments and Incentives: Accuray has appointed Paul Miele as Chief Commercial Officer and David Shin as Chief Legal Officer, granting them 650,000 and 375,000 restricted stock units (RSUs) respectively, reflecting the company's commitment to investing in its executive team.
- Performance Incentive Structure: The performance-based restricted stock units (PSUs) awarded to Miele and Shin will vest based on performance targets set for the fiscal year ending in 2028, aiming to enhance executive motivation and align their interests with overall company performance.
- Equity Incentive Plan Details: Miele's RSUs will vest starting April 30, 2027, with one-fourth unlocking annually, while Shin's RSUs will begin vesting on January 29, 2027, ensuring both executives contribute value throughout their tenure.
- Company Strategic Direction: Accuray is dedicated to improving patient lives through innovative radiation therapy solutions, and these executive incentives not only enhance management stability but also reflect the company's strategic commitment to ongoing innovation and market expansion in the radiation therapy sector.
See More
Accuray Partners with University of Wisconsin for Cancer Treatment Innovation
- Strategic Collaboration: Accuray has signed a 10-year strategic collaboration agreement with the University of Wisconsin School of Medicine to leverage its Stellar™ adaptive radiation therapy platform for advancing personalized cancer treatments, marking a deepening of their long-standing partnership in precision radiation therapy technology development.
- Clinical Research Support: This collaboration will support clinical research, education, and the development of adaptive therapies, enabling medical teams to continually raise the standard of cancer care, thereby improving patient treatment outcomes and quality of life.
- Legacy and Innovation: Since the late 1980s, technology invented by the University of Wisconsin's professor team has been commercialized into Accuray's TomoTherapy® system, ushering in a new era in radiation medicine that enhances treatment precision and accuracy.
- Future Outlook: The partnership aims to accelerate the translation of research innovations into clinical practice, leveraging a robust academic-industry collaboration to advance personalized radiotherapy technologies that better serve patient needs.
See More
Accuray Shares Plunge 27% After Q3 Fiscal 2026 Earnings Miss Expectations
- Earnings Decline: Accuray reported total net revenue of $104.8 million for Q3, a 7% year-over-year decline that missed Wall Street expectations, resulting in a 27% drop in share price.
- Weak Product Sales: Product revenue fell 13% to $49.7 million, while service revenue slipped 1% to $55.1 million, indicating significant competitive pressures in the market.
- Rising Operating Costs: Operating expenses increased by 12% year-over-year to $34.4 million, which included $6.5 million in restructuring charges, exacerbating the company's financial strain.
- Withdrawal of Financial Guidance: Citing geopolitical uncertainties in key Middle Eastern markets, Accuray withdrew its financial outlook, with the CEO indicating a cautious approach to future performance assessments.
See More
Accuray Q3 Fiscal 2026 Earnings Call Insights
- Revenue Performance: Accuray reported total revenue of approximately $105 million for Q3, reflecting a 3% sequential increase but a 7% year-over-year decline, indicating market challenges amid geopolitical uncertainties.
- Product Shipment Delays: Shipments planned for customers in the Middle East, North Africa, and Pakistan have been indefinitely delayed due to geopolitical disruptions, which are expected to negatively impact service revenue and increase future performance uncertainty.
- Guidance Withdrawal: Management's decision to withdraw financial guidance reflects insufficient visibility on future revenue and adjusted EBITDA, with an expectation to realize at least $25 million in structural profitability improvements in fiscal 2027.
- Margin Pressure: The overall gross margin for the third quarter was 24.1%, down from 27.9% in the prior year, primarily due to increased parts consumption and tariff impacts, highlighting challenges in cost control.
See More
Accuray Inc. Withdraws FY2026 Financial Guidance Amid Geopolitical Uncertainty in the Middle East - SEC Filing
Financial Guidance Update: The financial guidance for FY 2026 has been withdrawn due to increasing geopolitical uncertainty in the Middle East.
Impact of Geopolitical Factors: The decision to withdraw guidance reflects concerns over the potential impact of regional instability on financial forecasts.
See More
Accuray Appoints New Chief Commercial Officer
- Executive Appointment: Accuray announced the appointment of Paul Miele as Chief Commercial Officer effective April 6, 2026, tasked with leading the global commercial organization to drive transformation and enhance execution, thereby improving market competitiveness.
- Extensive Experience: Miele brings nearly two decades of global commercial leadership experience in the medical technology sector, having previously served as Business Unit Leader at Johnson & Johnson MedTech, where he successfully reversed a revenue decline trend and achieved double-digit annual sales growth.
- Strategic Objectives: As Chief Commercial Officer, Miele will define and execute Accuray's global commercialization strategy across sales, marketing, pricing, and market access, aiming to enhance the company's commercial impact in over 70 countries worldwide.
- Commitment to Innovation: Accuray is dedicated to improving cancer treatment through continuous innovation, and Miele's addition is expected to further drive growth in systems and services sales, particularly in providing value-added solutions to customers.
See More
